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ever in his wildest dreams had Fred vom Saal pictured 
himself studying urethral outlet obstruction. Nor, 
for that matter, had he ever thought much about 
the causes of obesity. For most of his 30-year career, vom 
Saal, a developmental biologist at the University of Missouri, 
studied the harmful consequences of tiny changes in natural 
hormone levels at critical periods during the development 
of the brain and reproductive tract. But he began to include 
synthetic chemicals in his investigations when he learned that 
pesticides and other environmental contaminants caused 
reproductive defects in wildlife much like those seen in lab 
animals exposed to abnormal estrogen levels. 
During embryonic development, steroid hormones like 
estrogen control gene-expression programs to coordinate 
cell differentiation, growth, organogenesis, and metabolism. 
Adding extra estrogen—whether foreign (exogenous) 
or natural (endogenous)—can irreversibly alter these 
developmental processes by mimicking, blocking, or 
otherwise disrupting pathways that have been ﬁ  ne-tuned 
over millions of years to respond to minuscule changes in 
hormone levels. Diethylstilbestrol (DES) offered a tragic 
illustration of the risks of exposing a fetus to synthetic 
compounds that mimic the behavior of endogenous estrogen: 
the drug was prescribed to millions of pregnant women 
before doctors realized it was causing rare cancers in their 
daughters.
To understand how exogenous estrogens interfere with 
developmental pathways, vom Saal started by feeding 
pregnant mice minute doses of DES, along with the 
endogenous estrogen estradiol, which he had long studied. In 
both cases, giving the mother these estrogens when prostate 
development is occurring raised fetal estrogen levels ever 
so slightly, with profound consequences: male offspring 
experienced accelerated prostatic gland growth and showed 
permanent increases in both the number of androgen 
receptors (androgen mediates prostate differentiation) and 
the size of the prostate [1].
But it wasn’t until vom Saal reported similar effects from a 
synthetic chemical still in mass production that his research 
focus, and his life, would take an unexpected turn. In 1997, 
vom Saal’s group reported that feeding pregnant mice trace 
amounts of bisphenol A—the building block of polycarbonate 
plastics—caused enlarged prostates in male offspring, just as 
estradiol and DES had. “Our ﬁ  ndings,” the researchers wrote, 
“show for the ﬁ  rst time that fetal exposure to environmentally 
relevant parts-per-billion (ppb) doses of bisphenol A, in the 
range currently being consumed by people, can alter the 
adult reproductive system in mice”[2]. 
The next year, vom Saal’s group showed that a similar 
treatment with bisphenol A also shrinks seminal vesicles, 
enlarges preputial glands (which produce sex pheromones), 
and reduces sperm efﬁ  ciency [3]. The 1998 study, which 
observed these effects at a dose six times lower than a patient 
might swallow during application of a plastic dental sealant, 
immediately caught the attention of the chemical industry—
and transformed Fred vom Saal into a tireless crusader 
against bisphenol A.
An Obscure Chemical Enters the Limelight
For over 40 years, bisphenol A labored in relative obscurity 
as the feedstock for a wide range of commercial plastics and 
synthetic resins. Growing demand for polycarbonates—for 
products ranging from baby bottles to compact discs—
drives the rapidly expanding multibillion-dollar market 
for bisphenol A, one of the highest-volume chemicals in 
commercial production [see related essay (published online 
17 July 2007); doi:10.1371/journal.pbio.0050200]. Bisphenol 
A molecules, which are joined by unstable bonds to form 
polycarbonates and resins, leach from containers exposed 
to heat or highly acidic or basic compounds. Although 
bisphenol A’s estrogenic activity was ﬁ  rst reported in 1936, 
scientiﬁ  c interest in the chemical has recently increased along 
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with evidence of its effects. And as the media increasingly 
cover these ﬁ  ndings, the chemical industry has stepped up its 
attacks on those studying endocrine disruption. 
“The moment we published something on bisphenol A, the 
chemical industry went out and hired a number of corporate 
laboratories to replicate our research. What was stunning 
about what they did,” vom Saal says with a mix of outrage and 
bemused disbelief, “was they hired people who had no idea 
how to do the work. Each of the members of these groups 
came to me and said, ‘We don’t know how to do this, will you 
teach us?’”
Vom Saal videotaped his protocols for a group hired by 
Dow Chemical, and sent one of his students to England 
to teach AstraZeneca scientists the system. By 1999, a 
ﬂ  urry of studies appeared from AstraZeneca [4–8], along 
with a collaborative effort sponsored by the Society of the 
Plastics Industry (SPI) from the labs of Dow, Shell, General 
Electric, and Bayer, the major bisphenol A producers [9]. 
(AstraZeneca does not make bisphenol A, but it produces 
a number of pest-control products that could face similar 
scrutiny.) None of the studies found that low doses of 
bisphenol A harm the developing prostate. 
The next year, however, a study came out that supported 
vom Saal’s ﬁ  ndings [10]. Channda Gupta, then a professor 
of pharmacology at the University of Pittsburgh School of 
Medicine, fed pregnant mice low doses of bisphenol A, 
aroclor (an estrogenic pesticide), and DES, which she used as 
a positive control, as vom Saal had. (If animals fail to respond 
to DES, whose effects are well understood, it’s a sign that 
the setup is ﬂ  awed.) Gupta also observed increased prostate 
size and gland number in male offspring. When she placed 
the developing prostate in culture and treated it with the 
chemicals, she saw the same abnormal prostatic growth—
indicating that the chemicals targeted the prostate directly.
Now vom Saal has gone even further with his rodent 
studies to show that bisphenol A activates androgen and 
estrogen receptor genes in the embryonic cells that give 
rise to prostate tissue [11]. This gene activity accelerates the 
proliferation of epithelial cells in prostate ducts, inducing 
prostate growth, and permanently increases the number of 
androgen receptors. “One of the consequences of that is that 
cells become hyper-responsive to hormones for the rest of the 
life of the individual,” he explains, “and that’s a risk factor for 
humans for prostate cancer.” The overgrown prostate ducts 
also squeeze the urethra, constricting its passage out of the 
bladder—a condition similar to bladder outlet obstruction 
disease.
The year after Gupta’s study appeared in Experimental 
Biology and Medicine, the journal ran a commentary, written by 
Barbara Elswick, Frederick Miller, and Frank Welsch of the 
Chemical Industry Institute of Toxicology (CIIT), faulting 
her analytical methods and conclusions [12]. The CIIT was 
“created by farsighted chemical industry leaders,” according 
to its Web site, and is funded by the American Chemistry 
Council (ACC). The CIIT scientists, who no longer work at 
the institute, could not be reached for comment.
Gupta’s response defended her original conclusions and 
pointed out: “It is interesting to note that the studies that 
failed to ﬁ  nd an effect of this chemical are funded by the 
chemical industries, whereas positive ﬁ  ndings are reported 
by independent academic laboratories. What is also clear is 
that scientists who choose to study a chemical of commercial 
importance are subjected to intense scrutiny by the chemical 
industry and by the scientists funded by these industries” 
[13].
Low-Dose Effects: A Manufactured Controversy?
Endocrinologists know that hormones normally 
stimulate their receptors at low concentrations, while 
high concentrations can inhibit these pathways by 
saturating receptors. But the notion that a substance can 
produce effects at low levels that disappear at higher 
levels fundamentally challenges traditional toxicological 
approaches. Faced with conﬂ  icting reports of harm from a 
chemical in mass circulation, the Environmental Protection 
Agency (EPA) asked the National Toxicology Program 
(NTP) to review the evidence on bisphenol A. If the panel 
decided the evidence was compelling, it would mean that 
the EPA’s current risk-assessment methods, which assume 
“the dose makes the poison,” are outdated. It would also 
mean that a signiﬁ  cant share of the chemical industry’s 
portfolio of pesticides and industrial chemicals—many 
of which are suspected endocrine disruptors—would be 
subject to a new standard of risk assessment, with potentially 
substantial ﬁ  nancial implications.
The EPA estimates safe human exposures to a chemical 
based on animal studies that ﬁ  nd the lowest harmful dose 
and the highest benign dose, then dividing one of the doses 
by a safety factor to account for variable human sensitivities 
and uncertainties in extrapolating to humans. Experiments 
from the 1980s, which found the lowest harmful dose at 50 
milligrams of bisphenol A per kilogram body weight per day, 
were used to calculate the current safe dose of bisphenol 
A (50 micrograms bisphenol A per kilogram body weight 
per day). “It’s just through hand waving that the regulatory 
community says if you divide that number by 1,000 that it’s a 
safe human exposure dose,” vom Saal says. “The public is told 
it’s a safe dose, but nobody ever tests that.”
In its initial review in 2001 [14], the NTP panel decided 
there was “credible evidence” that low doses of bisphenol A 
can cause effects on speciﬁ  c endpoints, but that the effects 
had not been “conclusively established as a general or 
reproducible ﬁ  nding.” This equivocal conclusion did not sit 
well with industry groups, so the American Plastics Council 
(APC) commissioned its own review from the Harvard Center 
for Risk Analysis (HCRA), which has received funding from 
all the major bisphenol A producers and their trade groups 
[see the Box]. 
HRCA Director Joel Schwartz acknowledges that taking 
money from industries with a direct ﬁ  nancial interest in a 
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study’s outcome is problematic. “We’re not averse to getting 
money from industry, but it used to be that the money 
predominantly came from industry, and I don’t think that’s 
a good idea,” he says. “So we’re trying to diversify, and one of 
the things we’re trying to avoid is getting the phone company 
to pay for a study of cell phones and the diesel company to 
pay for a study of diesel engines.” 
The HCRA report, commissioned before Schwartz’s tenure, 
concluded that “the weight of the evidence for low-dose 
effects is very weak” [15]. Industry groups hailed the report 
as a comprehensive review by independent experts and 
quickly disseminated its ﬁ  ndings. Yet the “comprehensive” 
report reviewed just 19 of 47 studies available in April 2002, 
and when it was published more than two years later, three 
panelists asked not to be listed as authors. 
In a 2005 commentary, vom Saal and Claude Hughes, a 
reproductive endocrinologist who had served on the HCRA 
panel, argued that the report was already obsolete when it 
came out [16]. By the end of 2004, they had identiﬁ  ed 115 
published studies on low doses of bisphenol A. They also 
found a troubling trend. Ninety percent of government 
studies found signiﬁ  cant effects of bisphenol A at doses below 
the EPA’s lowest adverse effect level, but not a single industry 
study found any effect. Many of the industry studies, they 
pointed out, either used a rat strain with very low sensitivity to 
estrogen or misinterpreted failure to ﬁ  nd effects with positive 
controls. Vom Saal and Hughes urged the EPA to conduct a 
new risk assessment on bisphenol A. 
Hughes was unaware of the HCRA’s historic ties with 
industry when he was asked to serve on the panel—“It said 
Harvard, I said legit, and showed up”—but having worked 
in the pharmaceutical industry, Hughes, now chief medical 
ofﬁ  cer and vice president of RTI International, is sensitive 
to charges of industry bias. “I’ve had to remind people that 
we also pointed out that government-sponsored studies 
on bisphenol A have tended to be mostly positive. Is that a 
bias? You want good results so you get your grant renewed, 
don’t you?” Hughes thought that raising the question of bias 
for stakeholders on both sides would trigger “the type of 
comprehensive review I had hoped would occur a few years 
ago. . . which was not something our small committee in 
Boston could begin to pull off.” 
The HCRA panel focused mostly on “whole-animal 
toxicological studies,” which look at different endpoints than 
the more mechanistic studies do, Hughes says. “That doesn’t 
let you look at changes in gene expression, changes in 
epigenetic control of gene expression. It doesn’t let you look 
at what, say, for a human population might be of concern.”
Vom Saal and Hughes’s call for a new risk assessment 
triggered another APC-sponsored report on bisphenol 
A, this time from Gradient Corporation [see the Box]. In 
2006, Gradient issued its “updated weight of the evidence 
evaluation,” which the authors called an extension of the 
HCRA report [17]. And like the HCRA report, the review 
often cited studies that lacked positive controls or used the 
insensitive rat strain to conclude that bisphenol A produces 
no adverse effect on any endpoint. In one case, the authors 
acknowledged a ﬁ  nding of decreased sperm counts, but 
argued that it was unclear whether such an effect could be 
considered adverse. In reviewing evidence of chromosomal 
abnormalities, the report excluded a much-publicized study 
by geneticist Patricia Hunt [18]—which showed that low 
levels of bisphenol A trigger substantial increases in improper 
chromosome segregation—on the grounds that the study 
didn’t measure a developmental or reproductive endpoint. 
The authors did not explain how chromosomally abnormal 
oocytes might produce normal individuals. 
Stepping into a Quagmire
Hunt, now with the School of Molecular Biosciences at 
Washington State University, started studying bisphenol A 
when she ran an experiment one week with normal results 
and then ran it the next, “and the control numbers were just 
completely bonkers.” Sterilizing the animals’ cages with high 
heat and accidentally washing them with a high pH soap 
damaged their polycarbonate cages and water bottles. Hunt 
found that bisphenol A leached from the water bottles and 
into their drinking water, and likely contaminated their food 
and penetrated their skin. Rather than pinpoint the exposure 
routes, however, she wanted to determine whether bisphenol 
A caused the anomaly. She did that by deliberately exposing 
her mice to bisphenol A. 
After publishing her results, Hunt says, industry “paid 
people to read our paper and provide talking points, things 
they could use to say, ‘Well, we aren’t really sure about this, 
and well, they didn’t do that, and this is suspicious.’ It was 
such a learning experience for me because I had never had 
a piece of my work scrutinized in such detail, and I always 
thought my scientiﬁ  c peers were going to be the ones who 
were going to be most critical.” Hunt had been “peripherally 
aware” of the disputes between academics studying endocrine 
disruption and industry, “but you never knew whether these 
people were credible scientists or not, and then when you 
step your own foot into it and you watch, industry really did 
try to run damage control on our work.” 
At the time, Hunt was studying chromosomal alignment 
in eggs undergoing division before ovulation. “Instead of 
lining up normally as they should, they were just not lining 
up at all,” Hunt explains. “We happened to be doing another 
set of studies where we were looking at eggs that completed 
the division and counting the chromosomes to see if they 
were normal or abnormal, and suddenly that data changed 
too. So we had two completely separate studies where we 
were studying what we thought were the precursors of the 
chromosomally abnormal egg, which would give rise to, for 
example, Down syndrome, and both sets of data showed us 
this sudden spike of abnormalities in completely normal 
mice.”
Hunt decided to test bisphenol A’s effects on the initial 
stages of egg development [19], thinking she wouldn’t ﬁ  nd 
any, since no one thought that estrogen played a role in 
mediating these very early steps of chromosomal interactions 
during oogenesis. “But of course, we were completely 
wrong,” Hunt says. Exposing pregnant mice to bisphenol 
A “had a very striking effect on the very early stages of egg 
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Ever since Rachel Carson ﬁ  rst warned that synthetic chemicals 
pose long-term health risks, the chemical industry has defended 
its products by attacking the credibility of scientists reporting 
ill effects. This strategy involves hiring consultants and 
commissioning reviews that dispute the ﬁ  ndings or minimize 
potential human risks from the chemical under study. 
Founded in 1989, the Harvard Center for Risk Analysis (HCRA) 
long specialized in minimizing human health risks from its 
benefactors’ products, starting with the tobacco industry. 
Internal documents released through the 1998 Tobacco Master 
Settlement Agreement reveal how HCRA founder John Graham 
signaled industry that its business was his business. In a 1991 
fund-raising letter seeking US$25,000, Graham told Philip 
Morris’s vice president of government affairs of his need “to learn 
more about the risk-related challenges that you face.” 
Graham got his US$25,000 after a company scientist 
recommended meeting Graham because “he’s a key player 
in all this risk analysis stuff that’s currently going on in the 
government.” (Philip Morris had to reissue the check through 
one of its subsidiaries after Graham learned that the Harvard 
School of Public Health prohibited taking tobacco industry 
money.) The next year, according to a report from Public 
Citizen, Graham wrote to a top White House policy counsel 
ofﬁ  cial questioning whether an EPA report on the health risks of 
second-hand smoke relied on good science. In widely reported 
public statements, including testimony before the US Senate 
Regulatory Affairs Committee, Graham has characterized the 
HCRA’s work as promoting a more reasoned public response to 
health, safety, and environmental hazards.
Gradient Corporation, the environmental consulting ﬁ  rm 
that wrote the HCRA follow-up review on bisphenol A, also cut 
its teeth on the tobacco industry. In the early 1990s, Gradient 
received nearly US$700,000 from RJ Reynolds, according to 
internal documents released through the tobacco settlement, 
to estimate dose-response relationships “for the purpose of 
comparing the biological activity of the New Cigarette with the 
standard cigarette.” The two Gradient principals working on the 
project offered RJ Reynolds expertise in cigarette toxicology and 
inhalation toxicology.
Gradient’s game, says Richard Clapp, professor of 
environmental health at Boston University’s School of Public 
Health, is product defense. Its services include promoting 
industry positions in op-eds, providing expert testimony in 
court, legislative, and regulatory proceedings, and issuing 
scientiﬁ  c reports. “They wind up defending people who are 
worried about liability,” Clapp says, “though they would 
say they’re there to make sure that there’s sound science 
behind whatever regulatory steps or litigation happens in this 
country.”
Environmental and public health experts know about 
Gradient, Clapp says, “because we run up against them when 
they testify against regulating some air pollutant and we’re 
testifying in favor of it, and you realize, oh my god, we’re on 
opposite sides. This is exactly what happened to me when I 
testiﬁ  ed in the Salem City Council hearings that they ought to 
be putting more controls on the polluting smokestacks from a 
power plant in Salem, Massachusetts, because I said it’s releasing 
particulate matter and undoubtedly having an adverse impact 
on the health of the community. The Gradient guy got up and 
said, ‘You have no proof of that and these studies on which these 
models are estimating the effects on health, they’re all based on 
faulty science.’”
Lorenz Rhomberg, the lead author of Gradient’s follow-up 
to the HCRA bisphenol A report, wrote a 2006 op-ed in the 
San Francisco Chronicle opposing a proposed California ban 
(Assembly Bill 319) of children’s products made of plastics 
containing bisphenol A. The bill, Rhomberg argued, relied 
on “unproven speculation” and a “scientiﬁ  cally unorthodox 
hypothesis that tiny exposures of bisphenol A … might harm 
health.” AB 319 died in committee. 
Via email, Rhomberg contends that the low-dose hypothesis is 
unorthodox because “it does tend to contradict the conclusions 
from evaluation of the whole body of evidence, because no clear 
mechanism for special low-dose effects . . . has been elucidated, 
and because the idea that ultra-low doses can have a distinct set 
of responses from those engendered by high doses is indeed a 
speculation.” 
As of November 2006, 151 of 178 published low-dose animal 
studies reported harm from low-dose bisphenol A exposures. 
All of the studies reporting harm received government funding. 
In a 2006 lawsuit contesting a San Francisco ordinance banning 
toys and other plastic children’s products containing bisphenol 
A, Rhomberg ﬁ  led court declarations on behalf of the chemical 
industry and toymakers and retailers. He argued that “studies 
reporting effects are contradicted by other, more numerous 
studies, including the most comprehensive studies, that report 
the lack of [bisphenol A] effects on the same outcomes at similar 
doses.” Though the San Francisco ordinance passed, the section 
banning toys and children’s products made with bisphenol A 
was repealed.
Calling distinctions between industry- and government-
funded studies a “red herring,” Rhomberg insists that even 
government-funded studies fail to support the low-dose toxicity 
of bisphenol A. “To ﬁ  nd over 150 studies now showing that BPA 
causes detrimental reproductive developmental effects,” he 
writes, “one has to include any study that reported any effect 
at any dose while setting aside the fact that those same studies 
typically report no effects at other (higher or lower) doses for 
the same endpoint, and they usually ﬁ  nd no effect for a series of 
other endpoints that were also examined.” 
In the court declaration, Rhomberg also argued that there’s 
nothing to suggest that children would be more susceptible 
than adults to bisphenol A. “I think the mainstream opinion is 
that whether fetuses are particularly sensitive to a chemical is a 
chemical-speciﬁ  c issue,” he explains, “and there are many cases 
where there is no such special sensitivity.” 
The notion that children cannot metabolize chemicals 
as efﬁ  ciently as adults and are uniquely vulnerable to 
environmental toxicants is, in fact, widely accepted. Based 
on these principles, the National Children’s Study (NCS) was 
designed to follow 100,000 US children from early pregnancy 
through age 21 to understand environmental links to dramatic 
increases in a wide range of chronic childhood diseases, 
including neurodevelopmental disorders, obesity, asthma, male 
reproductive birth defects, and certain cancers. Bisphenol A is 
among the environmental pollutants the NCS plans to track.  
Skeptics for Hire 
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development” in the female fetus. “And this causes some real 
problems when those females become adults,” she explains. 
“So our data right now say there are several different times 
that are susceptible during development and that exposures 
during these times can dramatically disrupt chromosomal 
behavior and lead to chromosomally abnormal eggs.”
These ﬁ  ndings suggest that bisphenol A poses risks to an 
exposed mother’s fertility, the safety of her conceptions, and 
even to her grandchildren. In 2005, the Centers for Disease 
Control and Prevention (CDC) found bisphenol A in the 
urine of 95% of people tested [20], but Hunt is especially 
concerned that bisphenol A has been found in human 
blood, amniotic ﬂ  uid, and cord blood. “The levels we’re 
seeing in humans are really in the range of the levels we’re 
testing in the mouse, and this stuff in humans does a good 
job of walking across the placenta.” The fact that estrogen 
leaches from plastics “raises interesting questions about in 
vitro fertilization (IVF),” Hunt says. “There’s a big problem 
with aneuploidy [abnormal chromosome number] in IVF, 
and we’ve always assumed that part of that comes from the 
individuals . . . and the stimulation protocols themselves.” 
There are so many factors to control in IVF, she says, “they 
haven’t even gotten to the idea of endocrine disruptors.”
Hunt is counting on prospective epidemiological studies 
to understand bisphenol A’s effects on humans, and points 
to DES as proof that well-designed rodent studies can predict 
human risks. “We ‘ran the experiment’ with DES in humans 
ﬁ  rst and then we went back and did all the rodent studies, 
and we found that, wow, the rodent model really was a good 
model for all these exposed humans.”
“Of course, there are lots of differences between mice 
and humans,” Hunt allows. “Mice bear litters for one thing. 
But when it comes to growing eggs, and this whole process 
of meiosis, the similarities are so striking that it makes the 
mouse a really powerful model, because the process is highly, 
highly conserved.” 
The Problem with Plastics
Ana Soto and Carlos Sonnenschein have been worried 
about what might be leaching from plastics ever since an 
estrogenic contaminant derailed their experiments in 1989. 
They were studying how estrogens regulate cell proliferation 
when, unexpectedly, the cells proliferated in their serum-
supplemented medium whether or not estrogen was present. 
Previously, adding serum without estrogen inhibited the 
cells’ proliferation while adding estrogens countered this 
effect, indicating that proliferation is the dominant state of 
cells in multicellular organisms and could be controlled only 
by inhibitory factors. “This anomalous behavior had never 
happened to us,” says Soto, who studies breast cancer and 
mammary gland development at Tufts University. “We knew 
that the only thing that could produce that proliferation was 
estrogen, and we didn’t add it.”
After tracing the contaminant to the plastic tubes 
holding the culture media components, Soto contacted the 
manufacturer, which sent more tubes to test. When Soto 
and Sonnenschein sent their results to the manufacturer, it 
attributed the contamination to a new plastic formulation but 
refused to divulge the ingredients. “So we puriﬁ  ed it, and it 
turned out to be nonylphenol,” Soto says, “the ﬁ  rst estrogen 
discovered in plastic.”
Soto and Sonnenschein used the same cell line to test 
several other chemicals for estrogenic activity and found 
that many of them, like nonylphenol, behaved like estrogen. 
“And then we decided to ask a question,” Soto says. “If you 
give a hormone to an adult and then you stop, the effects 
for the most part regress. . . . But if you give something 
during development, you will produce alterations that persist 
throughout life, because you are altering the formation of 
the organism; not just the function, but the building of the 
organism. So we decided to study bisphenol A and whether 
it would affect the female genital tract, the mammary gland, 
and the neuroendocrine system.”
Soto exposed pregnant rodents to “minuscule doses of 
bisphenol A, the same doses that humans are exposed to, 
according to the CDC.” In rats, this treatment produced 
overweight female offspring; in mice, adding the estrogenic 
chemical produced female offspring that behaved like males. 
Both rats and mice also had altered ovarian cycles. In a 
second round of experiments in mice, in utero bisphenol A 
exposures induced changes in mammary gland development 
that began in fetal life and persisted. “When they reach 
puberty and beyond, we observed that there is an increase in 
the structures where cancer arises, and there’s an increased 
sensitivity to estrogen,” Soto says. She also saw increased 
mammary duct density, the rodent equivalent to human 
mammographic density—a risk factor for women.
The mouse isn’t a good model for breast carcinogenesis, 
Soto explains, so she used rats to study mammary 
carcinogenesis. At environmental doses, in utero bisphenol A 
exposures “produced signiﬁ  cant increases in the amount of 
intraductal hyperplasias,” or preneoplastic lesions. At higher 
doses, she observed carcinomas in situ. “This parallels the 
ﬁ  nding that women exposed in utero to DES are now showing 
more propensity to develop breast cancer of the estrogen-
sensitive type.”
The changes in the breast and genital tract were expected, 
Soto says, but some of the behavioral effects and obesity came 
as a complete surprise. “We were looking at an estrogen 
thinking it was going to affect the reproductive system 
and mammary gland only, but then these two other things 
emerged without us ever imagining that.” 
Bisphenol A might induce epigenetic changes by altering 
patterns of DNA methylation, a chemical modiﬁ  cation 
that controls gene expression, or by activating or silencing 
genes at the moment of exposure during a critical period 
of development. Soto is pursuing these possibilities. “A 
single exposure during a point of vulnerability may sufﬁ  ce,” 
Soto says. “You know the thalidomide story. You can have 
thalidomide every day of your life and you will be ﬁ  ne. But 
“Now the industry will say that animals 
are not humans, which you can say as 
much as you wish, but that brings us 
to a situation; in order to know what 
is happening to humans, what are 
you going to do? Intoxicate pregnant 
women on purpose?” 
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[take it] at certain times during pregnancy, your child will 
end up with no arms.”
As far as Soto is concerned, bisphenol A threatens public 
health. “Now the industry will say that animals are not 
humans, which you can say as much as you wish, but that 
brings us to a situation; in order to know what is happening 
to humans, what are you going to do? Intoxicate pregnant 
women on purpose? In any case, we’re already exposing 
people, because 95% of us have bisphenol A in our urine, so 
the experiment cannot even be done.”
The Chemical Link to Obesity
For the most part, researchers investigating endocrine 
disruption had focused primarily on behavioral and 
reproductive consequences. But over the past few years, 
it’s become clear that some of the synthetic chemicals that 
disrupt the endocrine system also induce weight gain [21]. 
What’s more, production of these chemicals closely tracks 
the rise of obesity. Retha Newbold started studying the 
reproductive consequences of in utero DES exposure after 
physicians stopped prescribing the drug in 1971. She always 
noticed her animals were heavy, as Soto had, but didn’t 
think much of it. “It’s one of those things that if you’ve been 
working with your mice for 30 some years, you notice right 
off,” says Newbold, a developmental biologist at the National 
Institute of Environmental Health Sciences Environmental 
Toxicology Program. “I can tell you simply by the size of the 
animal which is DES-exposed and which isn’t.”
Newbold’s lab was among the ﬁ  rst to publish animal studies 
showing adverse effects in male offspring exposed to DES 
in the womb. “At that point, clinicians started looking at the 
male offspring [of mothers who took DES], and they had very 
similar things to what we were reporting in the mouse model,” 
Newbold says, including retained testes and hypospadias. She 
also studied DES’s effect on the female mouse reproductive 
tract, and found various genital lesions, malformations, and 
abnormalities, as well as reduced fertility—replicating the 
aberrations reported in DES daughters. 
“I think everyone, including myself, always assumed that 
the reproductive tract was the target tissue. And now we’re 
beginning to realize that it isn’t the only target tissue,” 
Newbold says. “We found out that brain is a target, bone is 
a target . . . and now the new target is adipocytes.” During 
prenatal and neonatal development, adipocytes (fat cells) 
receive the instructions they need to function properly 
throughout life. “These conversations between cells, which 
are set up during prenatal development, that’s what’s being 
interrupted,” Newbold explains. “And that’s why we see these 
long-term changes.” 
Vom Saal discovered a link between estrogen and obesity 
when AstraZeneca scientists tried to replicate his results on 
bisphenol A and prostate development. “Now the chemical 
corporation people, who didn’t know where the prostate 
was, did not replicate the results,” vom Saal wryly notes. “But 
they did something very interesting. They produced obese 
animals.”
AstraZeneca scientists found no differences in the prostates 
of animals fed bisphenol A, DES, or normal mouse chow. Yet 
in 25 years of using that mouse strain, vom Saal had never 
seen an animal as big as those recorded by the AstraZeneca 
group. And, it turned out, all the rodent groups had enlarged 
prostates after all—which could explain why no differences 
were reported. The AstraZeneca scientists had achieved with 
normal food what vom Saal had done with bisphenol A. But 
how? 
It seemed plausible that estrogenic contaminants in 
the food had estrogenized the animals to the point where 
negative controls appeared treated and the other groups 
could no longer respond to DES and bisphenol A. Vom Saal 
tested different foods to understand how nutrients might 
inﬂ  uence estrogen pathways. When he removed all the 
soy-derived plant estrogens from the mother’s diet, he was 
astonished to see endogenous estradiol levels in the fetus rise, 
and the offspring become “horriﬁ  cally obese.” 
Adding the weak plant estrogens back in the diet 
suppressed the far more potent endogenous estradiol, 
he discovered, by inhibiting an enzyme required to make 
it. Feeding pregnant mice chow without plant estrogens 
mimicked the effect of giving them bisphenol A by 
stimulating increased production of estradiol. Yet when vom 
Saal fed estrogen to adult mice, their fat pads disappeared. 
What these results demonstrate, vom Saal explains, is that 
sensitivity to estrogenic chemicals, and their potential to 
cause harm, is very life-stage speciﬁ  c. That’s one reason he’s 
worried about supplemental estrogens during pregnancy: 
estrogen actually causes embryonic cells to differentiate into 
fat cells, a process called adipogenesis.
Recent evidence suggests that a class of ubiquitous 
environmental pollutants called organotins can also stimulate 
adipogenesis and interfere with energy balance [22]. Bruce 
Blumberg, associate professor of developmental and cell 
biology at the University of California, Irvine, calls these 
compounds “obesogens.” Organotins like tributyltin, once 
routinely painted on ship hulls to discourage barnacle growth, 
contaminate the marine food chain, causing sex reversal and 
other reproductive abnormalities in marine animals. 
Blumberg’s group discovered that organotins can activate 
two nuclear hormone receptors—peroxisomal proliferator-
activated receptor γ (PPARγ) and retinoid X receptor 
(RXR)—that co-regulate the expression of genes involved in 
lipid homeostasis and adipogenesis. Inappropriate activation 
of these receptors, Blumberg says, may promote long-term 
changes in fat cell behavior and number that favor obesity. 
“When animals are exposed prenatally to organotins, it 
reprograms their metabolism such that if they’re never 
again exposed, they still gain weight,” Blumberg says. “Even 
with normal diet and normal exercise, they get signiﬁ  cantly 
fatter than animals that are not exposed.” The same thing 
will happen with a variety of chemicals, he adds, not just 
organotins. 
“The big question is why. Is it because we’ve made more fat 
cells? We have some evidence that suggests that’s one thing 
that’s happening. Are the cells more efﬁ  cient at storing fat 
than they would be otherwise? Is the body predisposed to 
divert more calories into fat than would be otherwise, the so-
called thrifty phenotype?”
In the thrifty phenotype hypothesis, undernutrition in 
the womb programs metabolic systems to expect a postnatal 
world of undernutrition. From an evolutionary perspective, 
genes that promote insulin resistance (thereby limiting 
glucose uptake) and fat storage would prove advantageous in 
times of famine. But in a world of fast foods, empty calories, 
and supersized meals, the same genes would promote obesity, 
insulin resistance, and type 2 diabetes. Interestingly, a class of 
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drugs used to treat type 2 diabetes (called thiazolidinediones) 
activates PPARγ to reverse insulin resistance in muscle 
and liver, but in doing so increases fat mass by facilitating 
triglyceride uptake in adipocytes. 
When vom Saal generates growth-restricted mouse pups 
by exposing mothers to bisphenol A, the babies go through 
a “ballistic postnatal growth period.” A second group of mice 
starts out “really heavy” and stays that way. Vom Saal’s two 
types of obese mice have 430 genes with different activity 
in their fat cells, exhibit substantial differences in glucose 
tolerance and leptin levels (leptin regulates appetite and 
energy expenditure), and lose weight at different rates. 
Though understanding the underlying causes of these 
differences will take “multiple lifetimes of work,” vom Saal 
says, it’s clear that both animals end up heavy in entirely 
different ways, with entirely different physiological, fat 
metabolism, and regulatory systems. “We think that 
environmental chemicals like bisphenol A are likely to 
target subpopulations of individuals that are rendered very 
sensitive to these chemicals by virtue of their genes, genetic 
background, maternal–fetal interactions . . . and the amount 
of hormones they’re exposed to.” 
The connection between fetal growth restriction, 
environmental estrogens, and obesity risk may be especially 
relevant for infertile couples, who are increasingly opting for 
IVF. For various reasons, many IVF babies are born premature 
and growth-restricted. Vom Saal worries that exposing this 
“highly sensitive subgroup” of babies to environmental 
chemicals that lead to accelerated postnatal growth will 
permanently alter their capacity to metabolize even normal 
diets and predispose them, like the mice in his experiments, 
to a lifetime of obesity. 
Vom Saal acknowledges that trying to unravel all the 
“phenomenally complex” interactions and components that 
contribute to obesity is “like chipping away at the pyramid,” 
but he has no doubt that animal studies on bisphenol A’s 
effects have relevance to humans. “This chemical is harming 
snails, insects, lobsters, ﬁ  sh, frogs, reptiles, birds, and rats,” 
vom Saal says, “and the chemical industry is telling people 
that because you’re human, unless there’s human data, you 
can feel completely safe.”
For information on products containing bisphenol A, 
go to http:⁄⁄www.bisphenolafree.org/ (click on the Smart 
Plastics Guide) and http:⁄⁄www.ewg.org/reports/bisphenola/
execsumm.php.   
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